Skip to main content
TipRanks
Go Ultimate75% OFF

Syndax Pharmaceuticals (1T3) Stock Forecast & Price Target

4 Followers
See the Price Targets and Ratings of:

1T3 Analyst Ratings

Strong Buy
7Ratings
7Buy0Hold0Sell
Based on 7 analysts giving stock ratings to Syndax Pharmaceuticals in the past 3 months

1T3 Stock 12 Month Forecast

€33.48▲(326.21% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Syndax Pharmaceuticals in the last 3 months. The average price target is EUR 33.48 with a high forecast of EUR 51.98 and a low forecast of EUR 20.98. The average price target represents a 326.21% change from the last price of EUR 7.86.
Highest Price Target€51.98Average Price Target€33.48Lowest Price Target€20.98

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for DE:1T3
Price TargetArticle
UBS€30.10→€28.27buy259.87%UpsideAssigned11/20/26
H.C. Wainwright€32.83buy317.91%UpsideReiterated11/05/26
Stifel Nicolaus€36.48buy364.35%UpsideAssigned11/05/26
B. Riley Securities Analyst forecast on DE:1T3Unknown AnalystNot RankedB. Riley Securities€30.10buy283.09%UpsideInitiated11/04/26
Barclays€33.74buy329.52%UpsideReiterated11/03/26
Bank of America Securities€20.98buy167.00%UpsideReiterated11/02/26
Citi€51.98buy561.70%UpsideReiterated11/02/26
J.P. Morgan€40.13→€36.48buy364.35%UpsideReiterated08/11/26
TD Cowen―buy―Reiterated08/04/26
Goldman Sachs€31.01buy294.70%UpsideReiterated07/14/26
Guggenheim€28.27buy259.87%UpsideReiterated07/14/26
Jefferies€36.48→€33.74buy329.52%UpsideReiterated05/01/26
Mizuho Securities€41.04→€39.22buy399.17%UpsideReiterated03/30/26
BTIG€51.07buy550.09%UpsideReiterated01/02/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PALIPalisade Bio
RZLTRezolute
MDWDMediwound
OVIDOvid Therapeutics
DFTXDefinium Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Syndax Pharmaceuticals

3 Months
Success Rate10/19 ratings generated profit
53%
Average Return
+6.64%

Copying Justin Zelin's trades and holding each position for 3 Months would result in 52.63% of your transactions generating a profit, with an average return of +6.64% per trade.

1 Year
Anupam Rama
Anupam RamaJ.P. Morgan
Success Rate10/21 ratings generated profit
48%
Average Return
-0.52%

Copying Anupam Rama's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of -0.52% per trade.

2 Years
Anupam Rama
Anupam RamaJ.P. Morgan
Success Rate4/21 ratings generated profit
19%
Average Return
-23.35%

Copying Anupam Rama's trades and holding each position for 2 Years would result in 19.05% of your transactions generating a profit, with an average return of -23.35% per trade.

1T3 Analyst Recommendation Trends

010203040Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for 1T3
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy1818141414
Buy67720
Hold00001
Sell00000
Strong Sell00000
total2425211615

In the current month, 1T3 has received 14 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 1T3 average Analyst price target in the past 3 months is 33.48.

1T3 Financial Forecast

€-2€-1.5€-1€-0.5€0Q1 2026Q3 2026Q4 2026
High€-0.18
Consensus€-0.44
Low€-0.56

1T3 Earnings Forecast

Next quarter’s earnings estimate for 1T3 is -EUR 0.44 with a range of -EUR 0.56 to -EUR 0.18. The previous quarter’s EPS was -EUR 0.50. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

€59.2M€73.5M€87.9M€102.3M€116.6MQ1 2026Q3 2026Q4 2026
High€117M
Consensus€86.8M
Low€80.1M

1T3 Sales Forecast

Next quarter’s sales forecast for 1T3 is EUR 86.79M with a range of EUR 80.15M to EUR 116.62M. The previous quarter’s sales results were EUR 75.97M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

1T3 Stock Forecast FAQ

What is DE:1T3’s average 12-month price target, according to analysts?
Based on analyst ratings, Syndax Pharmaceuticals’s 12-month average price target is €33.48.
What is DE:1T3’s upside potential, based on the analysts’ average price target?
Syndax Pharmaceuticals has 326.21% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Syndax Pharmaceuticals a Buy, Sell or Hold?
Syndax Pharmaceuticals has a consensus rating of Strong Buy, which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
What is Syndax Pharmaceuticals’s share price target?
The average share price target for Syndax Pharmaceuticals is €33.48. This is based on 7 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €51.98, and the lowest forecast is €20.98. The average share price target represents a 326.21% increase from the current price of €7.856.
What do analysts say about Syndax Pharmaceuticals?
Syndax Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Street analysts.
How can I buy shares of Syndax Pharmaceuticals?
To buy shares of DE:1T3, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.